- Current use of hormone replacement therapy (HRT) is associated with a significantly lower risk for lung cancer incidence and disease-specific mortality in women with a history of smoking compared with women who had never used HRT.
Why this matters
- Protective benefits of HRT may decrease over time following discontinuation of HRT use.
- 77,911 women without lung cancer from the National Cancer Institute prostate, lung, colorectal, and ovary trial with a history of prior HRT use (n=50,248) or no HRT use (n=27,663).
- Funding: None.
- Lung cancer was diagnosed in 2.1% of never HRT users and 1.6% of ever HRT users.
- HRT ever-users had a significantly lower risk (adjusted HRs) for:
- Lung cancer: 0.876 (P=.022);
- Disease-specific mortality: 0.814 (P=.003); and
- All-cause mortality: 0.813 (P<.001>
- Among ever-smokers, HRT exposure was associated with decreased risk (HRs) for:
- Lung cancer: 0.748 (P<.001 and>
- Disease-specific mortality: 0.666 (P<.001 for both>
- Lung cancer: 0.842 (P=.007); and
- Disease-specific mortality: 0.800 (P=.004), respectively.
- Retrospective study.